Who
Steven Frank
Director
Company insider
Files Form 4 as: Director, BioCryst Pharmaceuticals; Director, Precigen.
In numbers
- Trades disclosed
- 89
- Buys
- 1
- Sells
- 0
- Bought
- $688K
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 10 Sep 2013
- Last trade
- 31 Aug 2026
- Last filed
- 2 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 31 Aug 2026filed 2 Sep 2026 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code A | $12K1,288 at $9.70 | filing |
| 31 Aug 2026filed 2 Sep 2026 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code A | $12K1,288 at $9.70 | filing |
| 11 Jun 2026filed 15 Jun 2026 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —15,294 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | BCRX BioCryst Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —33,540 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | BCRX BioCryst Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —33,540 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —15,294 at $0.00 | filing |
| 29 May 2026filed 2 Jun 2026 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code A | $11K1,262 at $8.91 | filing |
| 29 May 2026filed 2 Jun 2026 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code A | $11K1,262 at $8.91 | filing |
| 13 Mar 2026filed 16 Mar 2026 | PGEN PrecigenBiotechnology | SEC FORM 4 Code M | —71,839 | filing |
| 13 Mar 2026filed 16 Mar 2026 | PGEN Precigenoption or derivative · Biotechnology | SEC FORM 4 Code M | —71,839 at $0.00 | filing |
| 13 Mar 2026filed 16 Mar 2026 | PGEN Precigenoption or derivative · Biotechnology | SEC FORM 4 Code M | —71,839 at $0.00 | filing |
| 13 Mar 2026filed 16 Mar 2026 | PGEN PrecigenBiotechnology | SEC FORM 4 Code M | —71,839 | filing |
| 10 Mar 2026filed 12 Mar 2026 | PGEN PrecigenBiotechnology | SEC FORM 4 Code A | $50K14,245 at $3.51 | filing |
| 10 Mar 2026filed 12 Mar 2026 | PGEN Precigenoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,612 at $0.00 | filing |
| 10 Mar 2026filed 12 Mar 2026 | PGEN Precigenoption or derivative · Biotechnology | SEC FORM 4 Code A | —41,073 at $0.00 | filing |
| 10 Mar 2026filed 12 Mar 2026 | PGEN Precigenoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,612 at $0.00 | filing |
| 10 Mar 2026filed 12 Mar 2026 | PGEN Precigenoption or derivative · Biotechnology | SEC FORM 4 Code A | —41,073 at $0.00 | filing |
| 10 Mar 2026filed 12 Mar 2026 | PGEN PrecigenBiotechnology | SEC FORM 4 Code A | $50K14,245 at $3.51 | filing |
| 27 Feb 2026filed 3 Mar 2026 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code A | $11K1,285 at $8.75 | filing |
| 27 Feb 2026filed 3 Mar 2026 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code A | $11K1,285 at $8.75 | filing |
News
No headline names them, or the companies they trade most, lately.